Q4 2028
Ends Dec 31, 2028
Revenue
$0.8B
$0.8B to $0.8B
EPS
3.39
3.36 to 3.41
No analyst count
EPS: No analyst count
May 4, 11:08 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$260.00
+1.75% today
Window Change
+3.97%
Window
Jun 23, 2025 → May 14, 2026
Coverage: 226 bars · Jun 23, 2025 → May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bio-Rad Laboratories, Inc. (BIO-B) is a Healthcare stock with a market cap of $7.03B. The stock last traded around $260.00 and up 4.0% across the available one-year price window (Jun 23, 2025 → May 14, 2026). Baseline metrics include revenue growth of +0.7%, EPS growth of +142.6%, a dividend yield of 0.0%. What stands out right now is revenue +0.7%, EPS +142.6%, free cash flow +40.7% with operating margin 9.2% and ROIC 2.0%. Valuation already assumes a fairly strong business story at P/E 41.1 and price/sales 2.7. Stock Foundry combines BIO-B price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BIO-B
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BIO-B Max Drawdown
-20.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BIO-B and SPY.
EPS Consensus
3.39
Range 3.36 → 3.41
No analyst count
vs prior: +8.1%Revenue Outlook
$0.8B
Range $0.8B → $0.8B
No analyst count
vs prior: +8.9%Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from FMP.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.